<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110509006420N28</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-30</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of GnRH long-acting agonist protocols and GnRH antagonist protocol in controlled ovarian stimulation in in vitro fertilization in infertile women with poor ovarian response</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation and comparison of GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF from POSEIDON group3- 4: A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>170</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74745</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, using the simple randomization method using the Random Allocation1 software (http://random-allocation software.informer.com\1) and based on the simple randomization method, the list of samples in the two groups studied by the expert Statistics will be generated. In this software, in order to generate a list of random numbers, first specify the number of groups to be studied as 2 and the total number of samples required as 170 people, and then from the list of sample randomization methods, the method (simple randomization method in parallel group) by considering the same number of samples in the groups. Then a random list will be generated based on the groups and the number of samples in each group. Randomly and after obtaining informed consent by the researcher, they are assigned to two groups. The sealed envelope method is used for concealment. The envelopes are prepared as many samples as each envelope contains the name of the intervention group for each sample. Is.</study_design>
      <phase>3</phase>
      <hc_freetext>Infertility.</hc_freetext>
      <i_freetext>Intervention 1: The GnRH antagonist group will start from the second day of the menstrual cycle, the ultrasound of gonadotropin IU225-300 rFSH signal-F daily subcutaneous injection. Then, if there is a dominant follicle ≥ 14 mm, the GNRH antagonist (Cetrotide 0.25 mg) is prescribed and will continue until the ovulation trigger day. With ultrasound monitoring, when there are The average follicle is ≥17 mm or one follicle is 18 mm, 10,000 hCG units were injected to induce the final maturation of follicles on the same day. Endometrial thickness and serum E2 level were measured for all 34-36 hours after the trigger under general anesthesia and ovarian puncture will be performed by ultrasound. became. 72 hours after ovarian puncture, two three-day-old embryos will be transferred and the remaining embryos will be frozen. If there is  serum progesterone level ≥ 1.5ng/ml, all embryos will be frozen. Intervention 2: Intervention group: In the GnRH agonist long protocol group, they received a  zoladex 3.6 mg dose of GnRH depot analog sc from day 21 of the cycle before ovarian stimulation. From the second day of the menstrual cycle, the ultrasound of gonadotropin IU225-300 rFSH signal-F will be injected daily subcutaneously. The dose of the drug will be adjusted according to the response of the ovary and will continue until the ovulation trigger day. With ultrasound monitoring, whenThe average follicle is ≥17 mm or one follicle is 18 mm In order to induce the final maturation of the follicle, 10,000 units of HCG were injected on the same day. Endometrial thickness and E2 serum level were measured for all 34-36 hours after the trigger under general anesthesia and ovarian puncture will be performed under ultrasound guidance. 72 hours after ovarian puncture, two three-day-old embryos will be transferred and the remaining embryos will be frozen. If there is serum progesterone level ≥ 1.5ng/ml, all embryos will be frozen.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All participant data sets are to be shared

When:
2 months after the result publication

To whom:
In order to receive data or other study documents, researchers working in academic and scientific institutions are allowed to apply

Conditions:
To evaluate the accuracy of the data and use data to complete other researches

Where to obtain:
Yazd Reproductive Sciences Institute, Bouali Ave, Yazd, Iran

How to obtain:
Request from the Research Deputy, submitted to the Research Council of the Center if the request accepts its referral to the security and after completion of the relevant forms, the request is referred to the research experts and then get the data.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>maryam eftekhar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yazd Reproductive Sciences Institute, BouAl Ave,Safaeih، Yazd, Yazd Province</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۹۱۶۸۷۷۳۹۱</zip>
        <telephone>+98 35 3824 7085</telephone>
        <email>eftekhar@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>maryam eftekhar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yazd Reproductive Sciences Institute, BouAl Ave,Safaeih، Yazd, Yazd Province</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۹۱۶۸۷۷۳۹۱</zip>
        <telephone>+98 35 3824 7085</telephone>
        <email>eftekhar@ssu.ac.ir</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>IVF/ICSI candidates
Women who respond poorly to ovulation stimulation: ovarian reserve less than 1.2 ng/ml and AFC number less than 5 POSEIDON group 3-4
Women between the ages of 18 and 42</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>42 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>sever Asherman's history
Severe uterine adenomyosis
Egg donation cycles
Cases of severe male infertility (azoospermia)
Cases where surrogacy is used
Endocrine or metabolic diseases (hypothyroidism, hyperthyroidism)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The GnRH antagonist group will start from the second day of the menstrual cycle, the ultrasound of gonadotropin IU225-300 rFSH signal-F daily subcutaneous injection. Then, if there is a dominant follicle ≥ 14 mm, the GNRH antagonist (Cetrotide 0.25 mg) is prescribed and will continue until the ovulation trigger day. With ultrasound monitoring, when there are The average follicle is ≥17 mm or one follicle is 18 mm, 10,000 hCG units were injected to induce the final maturation of follicles on the same day. Endometrial thickness and serum E2 level were measured for all 34-36 hours after the trigger under general anesthesia and ovarian puncture will be performed by ultrasound. became. 72 hours after ovarian puncture, two three-day-old embryos will be transferred and the remaining embryos will be frozen. If there is  serum progesterone level ≥ 1.5ng/ml, all embryos will be frozen.</i_keyword>
      <i_keyword>Intervention group: In the GnRH agonist long protocol group, they received a  zoladex 3.6 mg dose of GnRH depot analog sc from day 21 of the cycle before ovarian stimulation. From the second day of the menstrual cycle, the ultrasound of gonadotropin IU225-300 rFSH signal-F will be injected daily subcutaneously. The dose of the drug will be adjusted according to the response of the ovary and will continue until the ovulation trigger day. With ultrasound monitoring, whenThe average follicle is ≥17 mm or one follicle is 18 mm In order to induce the final maturation of the follicle, 10,000 units of HCG were injected on the same day. Endometrial thickness and E2 serum level were measured for all 34-36 hours after the trigger under general anesthesia and ovarian puncture will be performed under ultrasound guidance. 72 hours after ovarian puncture, two three-day-old embryos will be transferred and the remaining embryos will be frozen. If there is serum progesterone level ≥ 1.5ng/ml, all embryos will be frozen.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical pregnancy. Timepoint: 4 weeks after embryo transfer. Method of measurement: sonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Rate of early abortion. Timepoint: the loss of the gestational sac or fetal heartbeat in clinically pregnant individuals prior to 8 weeks of gestational age. Method of measurement: sonography.</sec_outcome>
      <sec_outcome>نرخ حاملگی مداوم. Timepoint: the continuation of pregnancy after 12 wk of gestational age. Method of measurement: sonography.</sec_outcome>
      <sec_outcome>Chemical pregnancy. Timepoint: 2 weeks after embryo transfer. Method of measurement: pregnancy test.</sec_outcome>
      <sec_outcome>Implantation. Timepoint: After a positive pregnancy test. Method of measurement: sonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-10</approval_date>
        <contact_name>Ethics committee of Yazd reproductive Sience Institute- Shahid Sadoghi University of Medical Science</contact_name>
        <contact_address>Yazd Reproductive Sciences Institute, BouAl Ave,Safaeih، Yazd, Yazd Province Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
